by cognosadminteam | Jan 3, 2023 | News
3 JANUARY, 2023 Cognos Therapeutics announced it has finalized a definitive agreement with Nocturne Acquisition Corporation to take the company public on the Nasdaq Stock Exchange. LOS ANGELES, CA. It was announced today on several financial news outlets that Cognos...
by cognosadminteam | Jan 7, 2022 | News
7 JANUARY, 2022 Report Stresses The Need To Develop Better Methods of Delivery for Therapeutics for Brain-Based Diseases. LOS ANGELES, CA. In an article published on LabRoots. com, by Dr. Kathleen M. Kokolus, who holds a Ph.D. in Tumorolgy and works at the Roswell...
by cognosadminteam | Nov 2, 2021 | News
2 NOVEMBER, 2021 Co-Founder and CIO Josh Shachar Discusses the Evolution of the Cognos Vision In a recent presentation to the Cognos Shareholders, Josh Shachar, the Co-Founder and Chief Innovation Officer for Cognos Therapeutics presented a compelling vision for the...
by cognosadminteam | Nov 1, 2021 | News
Cognos Therapeutics Corp. Engages Maxim Group LLC for Investment Banking and Financial Advisory Services Cognos Therapeutics has signed a Letter of Engagement to retain Maxim Group LLC (“Maxim”) to provide financial advisory and investment banking services, including...
by cognosadminteam | Oct 28, 2021 | News
28 OCTOBER, 2021 Cognos Announces Addition of New Clean Room To Expand Its Development Capabilities Cognos Therapeutics announced today the addition of an ISO-7 Clean Room to their existing Los Angeles laboratory facility (WATCH THE OVERVIEW VIDEO NOW). The clean...
by cognosadminteam | Feb 27, 2019 | News
27 FEBRUARY, 2019 Dr. Susan Alpert, MD, PhD, Joins Cognos Therapeutics as Lead Regulatory Consultant Dr. Susan Alpert, MD, PhD, has been named Lead Regulatory Consultant for Cognos Therapeutics, Inc. Dr. Alpert is considered one of the top U.S. regulatory experts....
Recent Comments